REGN — Regeneron Pharmaceuticals Income Statement
0.000.00%
- $115.81bn
- $107.99bn
- $13.12bn
- 89
- 26
- 78
- 69
Annual income statement for Regeneron Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7,863 | 8,497 | 16,072 | 12,173 | 13,117 |
Cost of Revenue | |||||
Gross Profit | 7,081 | 7,377 | 13,866 | 10,871 | 11,301 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5,654 | 4,921 | 7,125 | 7,434 | 9,070 |
Operating Profit | 2,210 | 3,577 | 8,947 | 4,739 | 4,047 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2,429 | 3,810 | 9,326 | 4,859 | 4,199 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 |
Net Income Before Extraordinary Items | |||||
Net Income | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 22 | 30.4 | 74.1 | 42.5 | 36.4 |